Practice Changing Trials in Advanced Non-Small Cell Lung Cancer

Practice Changing Trials in Advanced Non-Small Cell Lung Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Treatment of Operable Locally Advanced NSCLC

February 28th 2018

EP. 2: Treatment of Unresectable Locally Advanced NSCLC

February 28th 2018

EP. 3: Surgery in the Context of Immunotherapy for Locally Advanced NSCLC

February 28th 2018

EP. 4: Potential for Use of Checkpoint Inhibitors in Early-Stage NSCLC

February 28th 2018

EP. 5: Checkpoint Inhibitors for Newly Diagnosed Stage 4 NSCLC

February 28th 2018

EP. 6: Pembrolizumab + Chemotherapy in Newly Diagnosed NSCLC

February 28th 2018

EP. 7: Immuno-Oncology Combination Therapy: Which Patients With NSCLC?

February 28th 2018

EP. 8: Quadruple Therapy for Newly Diagnosed NSCLC

February 28th 2018

EP. 9: Dual Checkpoint Inhibitor Therapy for NSCLC

February 28th 2018

EP. 10: Biomarkers for Selection of Immuno-Oncology Agents in NSCLC

February 28th 2018

EP. 11: New Standard for Treating Stage 4 EGFR+ NSCLC

February 28th 2018

EP. 12: Treatment of EGFR+ NSCLC Brain Metastases

February 28th 2018

EP. 13: Ongoing Research in EGFR+ NSCLC

February 28th 2018

EP. 14: New Standard of Care for ALK-Rearranged NSCLC

February 28th 2018

EP. 15: Sequencing Therapies for ALK-Rearranged NSCLC

February 28th 2018

EP. 16: Pearls of Wisdom for the Field of NSCLC

February 28th 2018

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

Five Under 5: Top Oncology Videos for the Week of 10/5/2026

GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026

FDA Grants Fast Track Designation to PSV359 for Advanced FAP-Positive Solitary Fibrous Tumors

Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma